To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).

961 described in SSc patients with pulmonary fibrosis's or by spontaneous release of interleukin-1 since these alterations may enhance T helper cell function in antibody synthesis. This report emphasizes that antinuclear anti-Scl-70 antibodies may distinguish not only the diffuse cutaneous subset of SSc, but also patients at risk ofdeveloping severe lung disease. REFERENCES 1 Fritzler NJ, Kinse...